nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab
|
Malmberg, Ruben |
|
|
23 |
12 |
p. e552-e561 |
artikel |
2 |
Aotearoa provides concrete examples for how to address inequities in health
|
Jenei, Kristina |
|
|
23 |
12 |
p. e524 |
artikel |
3 |
2022 ASTRO annual meeting
|
Gourd, Katherine |
|
|
23 |
12 |
p. 1490-1491 |
artikel |
4 |
Breast surgery after neoadjuvant chemotherapy: time for a change?
|
Spanheimer, Philip M |
|
|
23 |
12 |
p. 1477-1479 |
artikel |
5 |
Climate-driven Atlantic hurricanes create complex challenges for cancer care
|
Espinel, Zelde |
|
|
23 |
12 |
p. 1497-1498 |
artikel |
6 |
COP27 Climate Change Conference: urgent action needed for Africa and the world
|
Atwoli, Lukoye |
|
|
23 |
12 |
p. 1486-1488 |
artikel |
7 |
Correction to Lancet Oncol 2022; 23: 1490–91
|
|
|
|
23 |
12 |
p. e531 |
artikel |
8 |
Correction to Lancet Oncol 2022; 23: e480
|
|
|
|
23 |
12 |
p. e531 |
artikel |
9 |
Dexamethasone for cancer-related dyspnoea
|
Nishimura, Rumi |
|
|
23 |
12 |
p. e525 |
artikel |
10 |
Dexamethasone for cancer-related dyspnoea – Authors' reply
|
Hui, David |
|
|
23 |
12 |
p. e526 |
artikel |
11 |
Diffuse peritoneal myofibroblastoma mimicking tuberculous peritonitis
|
Yang, Yuhua |
|
|
23 |
12 |
p. e562 |
artikel |
12 |
Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial
|
Kuerer, Henry M |
|
|
23 |
12 |
p. 1517-1524 |
artikel |
13 |
Essential anticancer medicines for children: defining what matters most for Europe
|
Denburg, Avram |
|
|
23 |
12 |
p. 1479-1480 |
artikel |
14 |
Essential medicines for childhood cancer in Europe: a pan-European, systematic analysis by SIOPE
|
Otth, Maria |
|
|
23 |
12 |
p. 1537-1546 |
artikel |
15 |
Five fractions of SBRT for prostate cancer
|
Achard, Vérane |
|
|
23 |
12 |
p. e530 |
artikel |
16 |
Fluorouracil and dose-dense adjuvant chemotherapy in breast cancer: lessons learned from the 20-year-old GIM2 trial
|
Morganti, Stefania |
|
|
23 |
12 |
p. 1482-1484 |
artikel |
17 |
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial
|
Del Mastro, Lucia |
|
|
23 |
12 |
p. 1571-1582 |
artikel |
18 |
Gryt: amplifying more patient voices for better outcomes
|
Craig, David |
|
|
23 |
12 |
p. 1494 |
artikel |
19 |
High hopes for a healthier Brazil with Lula's third mandate
|
Triunfol, Marcia |
|
|
23 |
12 |
p. e533 |
artikel |
20 |
Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial
|
Guadagnolo, B Ashleigh |
|
|
23 |
12 |
p. 1547-1557 |
artikel |
21 |
International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic
|
Lee, Victor Ho-Fun |
|
|
23 |
12 |
p. e544-e551 |
artikel |
22 |
Intra-individual comparison of 18F-sodium fluoride PET–CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial
|
Bénard, François |
|
|
23 |
12 |
p. 1499-1507 |
artikel |
23 |
Long-term survival and cure fraction estimates for childhood cancer in Europe (EUROCARE-6): results from a population-based study
|
Botta, Laura |
|
|
23 |
12 |
p. 1525-1536 |
artikel |
24 |
Mechanisms, mitigation, and management of urinary toxicity from prostate radiotherapy
|
Martin, Jarad M |
|
|
23 |
12 |
p. e534-e543 |
artikel |
25 |
New survey and initiatives to support patients living with cancer
|
Das, Manjulika |
|
|
23 |
12 |
p. 1489 |
artikel |
26 |
25 organisations added to tobacco industry allies database
|
Burki, Talha Khan |
|
|
23 |
12 |
p. 1493 |
artikel |
27 |
Pembrolizumab as adjuvant therapy in non-small-cell lung cancer
|
Uprety, Dipesh |
|
|
23 |
12 |
p. e527 |
artikel |
28 |
Pembrolizumab as adjuvant therapy in non-small-cell lung cancer
|
Sorscher, Steven |
|
|
23 |
12 |
p. e529 |
artikel |
29 |
Pembrolizumab as adjuvant therapy in non-small-cell lung cancer
|
Ganguly, Shuvadeep |
|
|
23 |
12 |
p. e528 |
artikel |
30 |
Preoperative hypofractionated radiotherapy for soft tissue sarcoma
|
Roeder, Falk |
|
|
23 |
12 |
p. 1481-1482 |
artikel |
31 |
QT prolongation with anticancer drugs: a multimodal issue
|
Raschi, Emanuel |
|
|
23 |
12 |
p. e522 |
artikel |
32 |
QT prolongation with anticancer drugs: a multimodal issue – Authors' reply
|
Giraud, Eline L |
|
|
23 |
12 |
p. e523 |
artikel |
33 |
SABR for primary renal cell carcinoma: single-fraction or multiple-fraction?
|
Mizowaki, Takashi |
|
|
23 |
12 |
p. 1476-1477 |
artikel |
34 |
Stakeholders welcome proposal on the European Health Data Space
|
Das, Manjulika |
|
|
23 |
12 |
p. 1492 |
artikel |
35 |
Still waiting for a UK cancer plan that truly delivers
|
The Lancet Oncology, |
|
|
23 |
12 |
p. 1475 |
artikel |
36 |
Telling the personal stories behind cancer at the Edinburgh Festival Fringe
|
Ranscombe, Peter |
|
|
23 |
12 |
p. 1495-1496 |
artikel |
37 |
The Advisory Board on Cancer, Infertility and Pregnancy: a virtual on-demand multidisciplinary tumour board
|
Amant, Frédéric |
|
|
23 |
12 |
p. 1484-1486 |
artikel |
38 |
US cancer drug prices do not reflect benefits to patients
|
Furlow, Bryant |
|
|
23 |
12 |
p. e532 |
artikel |
39 |
5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)
|
Siva, Shankar |
|
|
23 |
12 |
p. 1508-1516 |
artikel |
40 |
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
|
Meric-Bernstam, Funda |
|
|
23 |
12 |
p. 1558-1570 |
artikel |